KRAS and chronic myelogenous leukemia, BCR-ABL1 positive: It was identified that the compound SIAIS562055 sustainably degraded SOS1 levels and inhibit downstream effectors, exhibiting potent antitumor activity in both KRAS-mutant cancers and BCR–ABL+ CML.